Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization and review

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Evolent review and prior authorization requirements for oncology medications and supportive agents for Wellcare by Fidelis Care Medicare members; applies to participating providers dispensing/administering drugs in pharmacy, physician office, outpatient hospital, or ambulatory settings.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2025
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent via the web portal or by phone for review before dispensing or administration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+HCPCS/CPT/J‑codes and oral drug entries listed requiring review
    All agesMember ages covered by review requirement
    Participating providersProvider network required to submit to Evolent prior to dispensing/administering
    6/1/2025Policy effective date for Wellcare by Fidelis Care

    Coverage and Submission Requirements

    Prior Review Requirement

    Covered when ALL of the following administrative conditions are met

    Evolent review and submission: The oncology medication or supportive agent is submitted to Evolent for review prior to dispensing or administration by participating providers.

    Submit the full oncology regimen (include all drugs and supportive agents). Use Evolent's web portal at my.newcenturyhealth.com or call 1-888-999-7713, option 1; non‑participating providers should submit to the plan via fax 1-844-235-5090.

    Do NOT submit the following categories to Evolent for review: antibiotics; bone marrow, stem cell transplants, and CAR‑T cell therapy; controlled substances (e.g., morphine); equipment requests (e.g., infusion pumps); genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    Agent (class)Preferred biosimilar / example (benefit)
    Erythropoiesis‑stimulating agentsRetacrit (medical benefit; if unavailable due to shortage: Epogen); Procrit (pharmacy benefit)
    TrastuzumabTrazimera (medical benefit); Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera (pharmacy benefit)
    BevacizumabMvasi, Zirabev (medical benefit); Avastin, Mvasi, Zirabev (pharmacy benefit)
    Hematopoietic agentsZarxio (medical & pharmacy benefit)
    RituximabRuxience, Truxima (medical benefit); Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima (pharmacy benefit)
    Bone agentsZoledronic acid, pamidronate (medical benefit); zoledronic acid, pamidronate, Prolia, Xgeva, risedronate, ibandronate (pharmacy benefit)
    Prostate cancer agentsEligard, Firmagon, Lupron, Trelstar, Vantas, Zoladex (medical benefit; nonpreferred: Provenge); Trelstar, Lupron, abiraterone acetate (pharmacy benefit; nonpreferred: abiraterone acetate micronized)
    BendamustineBendeka (pharmacy benefit)
    AntiemeticsAprepitant, dronabinol, ondansetron (IV and oral), granisetron (IV and oral), metoclopramide (IV and oral), prochlorperazine (IV and oral), scopolamine patch (pharmacy benefit)

    Codes and Drug Entries Requiring Review

    Listed HCPCS/J codes requiring reviewHCPCS
    C9302ZANIDATAMAB-HRII INJ (ZIIHERA)
    C9303ZOLBETUXIMAB-CLZB INJ (VYLOY)
    C9293GLUCARPIDASE
    J0185APREPITANT INJ
    J0207AMIFOSTINE INJ
    J0208SODIUM THIOSULFATE
    J0594BUSULFAN INJ
    J0641LEVOLEUCOVORIN INJ
    J0870IMETELSTAT (RYTELO)
    J0881DARBEPOETIN ALFA NON-ESRD
    1–10 of 17
    1/2
    Pharmacy benefit / oral agents requiring reviewmixed
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL (includes suspension and tripak)
    J8530CYCLOPHOSPHAMIDE ORAL
    J8565GEFITINIB
    J8600MELPHALAN ORAL
    J8655NETUPITANT/PALONOSETRON ORAL
    J8670ROLAPITANT, ORAL
    J8999Multiple oral oncology/targeted agents listed as J8999 entries (see source)
    J8520CAPECITABINE ORAL
    1–10 of 14
    1/2

    Provider Responsibilities and Submission Workflow

    Prior Authorization

    Prior authorization required for listed oncology drugs

    The listed HCPCS/J/CPT codes and specified oral agents require review by Evolent (prior authorization) regardless of formulary status before being dispensed or administered; some listed drugs will be processed as medical benefit and others as pharmacy benefit per the policy.

    • Providers must obtain Evolent review/prior authorization for the oncology medications and supportive agents listed by code (see coding tables).
    • This requirement applies regardless of formulary status and applies to both medical- and pharmacy-benefit drugs as noted in the document.
    Step Therapy

    Preferred biosimilars — submit to Evolent for review

    Preferred biosimilar agents are identified in the policy; providers should submit requests for these preferred agents to Evolent for review.

    • Examples include Retacrit (erythropoiesis-stimulating agent), Trazimera (trastuzumab biosimilar), Mvasi (bevacizumab biosimilar), and Zarxio (hematopoietic agent).

    Out-of-Scope Categories and Key Terms

    Out of scope with Evolent — do not submit these items
    Do not submit these categories to EvolentAntibiotics; Bone marrow/stem cell transplants and CAR‑T cell therapy; Controlled substances (e.g., morphine); Equipment requests (infusion pumps); Genetic lab testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; Immune globulins.
    Preferred biosimilar — erythropoiesis-stimulating agentsMedical benefit: Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: Procrit.
    Preferred biosimilar — trastuzumabMedical benefit: Trazimera; Pharmacy benefit examples: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera.
    Preferred biosimilar — bevacizumabMedical benefit: Mvasi, Zirabev; Pharmacy benefit examples: Avastin, Mvasi, Zirabev.
    Preferred biosimilar — hematopoietic agentsMedical & Pharmacy benefit: Zarxio.

    Policy Background and Scope

    This policy governs administrative prior review and benefit routing for oncology medications and supportive agents. It establishes that participating providers must submit oncology regimens to Evolent for review prior to dispensing or administration; it is an administrative policy and does not provide clinical treatment guidance. Providers should submit the entire oncology regimen to Evolent, as omitting drugs may result in a denial.

    Policy Revision History

    2025-06-01Policy effective dateLatest

    Policy effective date for Wellcare by Fidelis Care established as 6/1/2025; oncology medications and supportive agents require Evolent review prior to dispensing or administration for participating providers.

    2023-10-01Administrative update

    New fax number for non‑participating providers updated to 1-844-235-5090 (replaced prior 1-877-882-5892).

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization and review
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2025
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent via the web portal or by phone for review before dispensing or administration.
    SourceLink
    On This Page
    Coverage and Submission RequirementsCodes and Drug Entries Requiring ReviewProvider Responsibilities and Submission WorkflowOut-of-Scope Categories and Key TermsPolicy Background and ScopePolicy Revision History
    Note

    Submission instructions — portal, phone, and non-participating provider fax

    Submit the entire oncology regimen to Evolent via the web portal at my.newcenturyhealth.com or by calling 1-888-999-7713 (option 1). Non-participating providers must submit requests to the plan via fax at 1-844-235-5090.

    • Use the portal or phone number for participating providers; non-participating providers should use the plan fax number listed.
    Denial Risk

    Complete regimen submission required — omission may cause denial

    Submit the complete oncology regimen to Evolent; omission of any drug(s) from the submitted regimen may result in a denial.

    • Include all agents (anticancer and supportive) in the single regimen submission to avoid denial for omitted drugs.
    Prior Authorization

    Evolent review required before dispensing/administration for participating providers

    Oncology medications and supportive agents must be reviewed by Evolent before being dispensed or administered for participating providers in pharmacy, physician office, outpatient hospital, or ambulatory settings.

    • This review requirement applies to members of all ages and covers requests submitted for clinical trials as well.
    • Participating providers must obtain Evolent review prior to dispensing or administration.